RDNT Stock Analysis: RadNet | NASDAQ

Diagnostics & Research | NASDAQ, USA | Market Cap: 5.580m USD | 12M Return: -0.3% | US7504911022 | Charts, Fundamentals & Technical Analysis

Diagnostic Imaging, AI Radiology, Medical Informatics, Cloud
Total Rating 37
Safety 71
Buy Signal -0.37
Diagnostics & Research
Industry Rotation: +7.9
Market Cap: 5.58B
Avg Turnover: 49.9M
Risk 3d forecast
Volatility39.1%
VaR 5th Pctl6.54%
VaR vs Median1.62%
Reward TTM
Sharpe Ratio0.14
Rel. Str. IBD63.4
Rel. Str. Peer Group31.7
Character TTM
Beta1.028
Beta Downside0.809
Hurst Exponent0.465
Drawdowns 3y
Max DD46.84%
CAGR/Max DD0.74
CAGR/Mean DD2.11
EPS (Earnings per Share) EPS (Earnings per Share) of RDNT over the last years for every Quarter: "2021-09": 0.21, "2021-12": 0.13, "2022-03": -0.15, "2022-06": 0.15, "2022-09": 0.09, "2022-12": 0.11, "2023-03": -0.08, "2023-06": 0.24, "2023-09": 0.14, "2023-12": 0.2, "2024-03": 0.07, "2024-06": 0.16, "2024-09": 0.18, "2024-12": 0.22, "2025-03": -0.35, "2025-06": 0.31, "2025-09": 0.2, "2025-12": 0.23, "2026-03": -0.28, "2026-06": 0.29,
EPS CAGR: -10.91%
EPS Trend: -33.0%
Last SUE: 1.04
Qual. Beats: 1
Revenue Revenue of RDNT over the last years for every Quarter: 2021-09: 332.69, 2021-12: 333.149, 2022-03: 341.767, 2022-06: 354.375, 2022-09: 350.044, 2022-12: 383.876, 2023-03: 390.564, 2023-06: 403.715, 2023-09: 401.968, 2023-12: 420.383, 2024-03: 431.707, 2024-06: 459.714, 2024-09: 461.142, 2024-12: 477.101, 2025-03: 471.399, 2025-06: 498.23, 2025-09: 522.869, 2025-12: 547.712, 2026-03: 575.631, 2026-06: 622.72,
Rev. CAGR: 13.28%
Rev. Trend: 99.3%
Last SUE: 1.90
Qual. Beats: 9

Warnings

High Debt/EBITDA With Thin Interest Coverage
High Debt While Negative Cash Flow
Altman Z'' In Financial Distress Zone
Below Avwap Earnings

Tailwinds

Shakeout

Seasonality 11.7 years of data

Jan -1.1% 17
Feb -1.1% 30
Mar -6.4% 19
Apr -0.0% 5
May +8.7% 46
Jun +4.4% 17
Jul -0.5% 8
Aug +6.2% 21
Sep +4.5% 39
Oct -4.1% 28
Nov +8.3% 18
Dec -0.5% 16

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: RDNT RadNet

RadNet, Inc. (NASDAQ: RDNT) is a Los Angeles-based provider of outpatient diagnostic imaging services, operating across the United States and internationally through two segments: Imaging Centers and Digital Health. Its clinical offerings span MRI, CT, PET, nuclear medicine, mammography, ultrasound, diagnostic radiology, and fluoroscopy, alongside multi-modality imaging services.

Beyond imaging delivery, RadNet develops and sells picture archiving and communication systems (PACS) for digital image management and has built out a growing portfolio of artificial intelligence tools designed to assist radiologists in interpreting breast, lung, and prostate images, as well as prostate cancer screening solutions. The company also offers AI-powered health informatics products, including DeepHealth OS, a cloud-native operating system intended to streamline radiology operations.

Founded in 1981 and publicly listed since 1986, RadNet sits within the Health Care Services sub-industry of the broader Health Care sector. Outpatient imaging centers like those operated by RadNet typically provide a lower-cost, more accessible alternative to hospital-based imaging, while the integration of AI-driven diagnostics represents a notable shift toward automation and standardization in radiology workflows.

Headlines to Watch Out For
  • DeepHealth AI suite revenue accelerates in digital health segment
  • Imaging center acquisitions drive top-line growth and market share gains
  • CMS reimbursement rate decisions pressure outpatient imaging procedure margins
Piotroski VR-10 (Strict) 3.5
Net Income: -21.1m TTM > 0 and > 6% of Revenue
FCF/TA: -0.01 > 0.02 and ΔFCF/TA -3.55 > 1.0
NWC/Revenue: 14.89% < 20% (prev 28.73%; Δ -13.84% < -1%)
CFO/TA 0.08 > 3% & CFO 317.0m > Net Income -21.1m
Net Debt (2.31b) to EBITDA (277.4m): 8.31 < 3
Current Ratio: 1.48 > 1.5 & < 3
Outstanding Shares: last quarter (78.7m) vs 12m ago 6.29% < -2%
Gross Margin: 9.70% > 18% (prev 11.64%; Δ -1.94% > 0.5%)
Asset Turnover: 58.62% > 50% (prev 54.28%; Δ 4.34% > 0%)
Interest Coverage Ratio: 1.49 > 6 (EBIT TTM 106.3m / Interest Expense TTM 71.3m)
Altman Z'' 1.02
A: 0.08 (Total Current Assets 1.04b - Total Current Liabilities 697.8m) / Total Assets 4.23b
B: -0.03 (Retained Earnings -121.4m / Total Assets 4.23b)
C: 0.03 (EBIT TTM 106.3m / Avg Total Assets 3.87b)
D: 0.39 (Book Value of Equity 1.10b / Total Liabilities 2.83b)
Altman-Z'' = 1.02 = BB
Beneish M -4.00
DSRI: 0.95 (Receivables 241.8m/212.9m, Revenue 2.27b/1.91b)
GMI: 1.20 (GM 11.64% / 9.70%)
AQI: -3.27 (AQ_t 0.37 / AQ_t-1 -0.11)
SGI: 1.19 (Revenue 2.27b / 1.91b)
TATA: -0.08 (NI -21.1m - CFO 317.0m) / TA 4.23b)
Beneish M = -5.29 (Cap -4..+1) = AAA
What is the price of RDNT shares?

As of October 13, 2026, the stock is trading at USD 71.49 with a total of 383,400 shares traded. Over the past week, the price has changed by +1.30%, over one month by -5.30%, over three months by +12.92% and over the past year by -0.32%.

Current recommended Stop Loss: 68.10 (which is 4.7% or 1.3 ATR below the current price).

Is RDNT a buy, sell or hold?

RadNet has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy RDNT.

  • StrongBuy: 6
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the RDNT price?
Analysts Target Price 94.6 32.4%
RadNet (RDNT) - Fundamental Data Overview as of 12 October 2026
Market Cap USD = 5.58b (5.58b USD * 1.0 USD.USD)
P/E Forward = 36.63
P/S = 2.4595
P/B = 5.3117
P/EG = 0.9574
Revenue TTM = 2.27b USD
EBIT TTM = 106.3m USD
EBITDA TTM = 277.4m USD
Long Term Debt = 1.30b USD (from longTermDebt, last quarter)
Short Term Debt = 100.2m USD (from shortTermDebt, last quarter)
Debt = 3.03b USD (from shortLongTermDebtTotal, last quarter) + Leases 850.2m
Net Debt = 2.31b USD (calculated: Debt 3.03b - CCE 726.3m)
Enterprise Value = 7.89b USD (5.58b + Debt 3.03b - CCE 726.3m)
Interest Coverage Ratio = 1.49 (Ebit TTM 106.3m / Interest Expense TTM 71.3m)
EV/FCF = -134.9x (Enterprise Value 7.89b / FCF TTM -58.5m)
FCF Yield = -0.74% (FCF TTM -58.5m / Enterprise Value 7.89b)
FCF Margin = -2.58% (FCF TTM -58.5m / Revenue TTM 2.27b)
Net Margin = -0.93% (Net Income TTM -21.1m / Revenue TTM 2.27b)
Gross Margin = 9.70% ((Revenue TTM 2.27b - Cost of Revenue TTM 2.05b) / Revenue TTM)
Gross Margin QoQ = 14.14% (prev -2.85%)
Tobins Q-Ratio = 1.87 (Enterprise Value 7.89b / Total Assets 4.23b)
Interest Expense / Debt = 2.35% (Interest Expense 71.3m / Debt 3.03b)
Taxrate = 44.90% (15.7m / 35.0m)
NOPAT = 58.6m (EBIT 106.3m * (1 - 44.90%))
Current Ratio = 1.48 (Total Current Assets 1.04b / Total Current Liabilities 697.8m)
Debt / Equity = 2.77 (Debt 3.03b / totalStockholderEquity, last quarter 1.10b)
Debt / EBITDA = 8.31 (Net Debt 2.31b / EBITDA 277.4m)
 Debt / FCF = -39.46 (negative FCF - burning cash) (Net Debt 2.31b / FCF TTM -58.5m)
 Total Stockholder Equity = 1.08b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.55% (Net Income -21.1m / Total Assets 4.23b)
RoE = -1.95% (Net Income TTM -21.1m / Total Stockholder Equity 1.08b)
RoCE = 4.46% (EBIT 106.3m / Capital Employed (Equity 1.08b + L.T.Debt 1.30b))
RoIC = 1.67% (NOPAT 58.6m / Invested Capital 3.52b)
WACC = 6.68% (E(5.58b)/V(8.61b) * Re(9.60%) + D(3.03b)/V(8.61b) * Rd(2.35%) * (1-Tc(0.45)))
Discount Rate = 9.60% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 80.48 | Cagr: 5.83%
 [DCF] Fair Price = unknown (Cash Flow -58.5m)
 EPS Correlation: -32.96 | EPS CAGR: -10.91% | SUE: 1.04 | # QB: 1
Revenue Correlation: 99.29 | Revenue CAGR: 13.28% | SUE: 1.90 | # QB: 9
EPS current Quarter (2026-09-30): EPS=0.22 | Chg30d=+0.00% | Revisions=-38% | Analysts=7
EPS current Year (2026-12-31): EPS=0.51 | Chg30d=+0.00% | Revisions=+10% | GrowthEPS=+31.9% | GrowthRev=+22.9%
EPS next Year (2027-12-31): EPS=0.89 | Chg30d=+0.00% | Revisions=-29% | GrowthEPS=+72.4% | GrowthRev=+10.1%
[Analyst] Revisions Ratio: -21% (up=6, down=10)